MARK3 and frontotemporal dementia: Using a smaller, independent cohort of patient tissue (Table 5 and Supplemental Table 6), we validated our finding of increased MARK3 RNA expression in the frontal cortex of ALS/FTD and FTLD-TDP patients relative to controls (Supplemental Figure 9, A and B).